BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new financing round of $55 million to add to its $119 million combined Series B and B1. New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners..

科罗拉多州博尔德市（商业新闻短讯）--Enveda Biosciences（“Enveda”）是一家利用人工智能将自然转化为新药的生物技术公司，今天宣布了新一轮5500万美元的融资，以增加其1.19亿美元的B系列和B1系列组合。。。

Enveda is a drug discovery and development company using the latest AI-powered technologies to translate nature into new medicines. The company’s proprietary platform solves – for the first time at scale – the long-standing obstacles in natural product drug discovery including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access..

Enveda是一家药物发现和开发公司，使用最新的人工智能技术将自然转化为新药。。。

This new funding will be used to support further development of Enveda’s breakthrough platform, which recently led to the nomination of a sixth New Chemical Entity (NCE) Development Candidate, and parallel Phase I clinical development of Enveda’s top 3 lead programs, which are slated to enter clinical trials later in 2024 and early 2025.

这项新资金将用于支持Enveda突破性平台的进一步开发，该平台最近导致提名了第六位新的化学实体（NCE）开发候选人，以及Enveda前三大领先项目的并行I期临床开发，计划于2024年晚些时候和2025年初进入临床试验。

Enveda’s lead program for atopic dermatitis is a novel oral first-in-class anti-inflammatory agent that has demonstrated remarkable efficacy and high safety margins in preclinical studies. Close on its heels is another novel first-in-class anti-inflammatory that inhibits multiple cytokine signaling cascades in the gut to achieve robust efficacy in models of inflammatory bowel disease..

Enveda针对特应性皮炎的领先项目是一种新型口服一流抗炎药，在临床前研究中显示出显着的疗效和高安全裕度。紧随其后的是另一种新型的一流抗炎药，可抑制肠道中的多种细胞因子信号级联反应，从而在炎症性肠病模型中取得强大的疗效。。

“At Premji Invest, we seek to partner with exceptional teams to build companies that can create long-term value. We are excited by Enveda’s potential to deliver new, safe and efficacious treatments for complex conditions, pushing the boundaries of AI and ML in life sciences,” said Sandesh Patnam, Managing Partner at Premji Invest.

Premji Invest管理合伙人桑德什·帕特南（SandeshPatnam）表示：“在Premji Invest，我们寻求与优秀团队合作，建立能够创造长期价值的公司。我们对Enveda为复杂疾病提供新的、安全有效的治疗方法的潜力感到兴奋，这将推动AI和ML在生命科学领域的界限。”。

“Enveda has made significant progress in creating a platform that learns from the diversity in natural chemistry and is able to translate this knowledge to develop novel therapeutics. We look forward to the new discoveries which can bring hope to millions of patients worldwide.”.

“Enveda在创建一个平台方面取得了重大进展，该平台可以从天然化学的多样性中学习，并能够将这些知识转化为开发新的治疗方法。我们期待着新的发现，这些发现可以为全球数百万患者带来希望。”。

“We're proud to support Enveda as we see its potential for long-term, open-ended growth due to the broad utility of their technology for solving some of the toughest challenges facing human and planetary health,” says Morgan Samet, Partner and Co-Head – Lingotto Investment Management. “Viswa is the type of founder we are excited to back, given his resourcefulness, tenacity, and vision.”.

Lingotto投资管理合伙人兼联席主管摩根·萨米特（Morgan Samet）表示：“我们很自豪能够支持Enveda，因为我们看到其技术在解决人类和地球健康面临的一些最严峻挑战方面的广泛应用，具有长期、开放式增长的潜力。”。“鉴于维斯瓦的足智多谋、坚韧和远见，我们很高兴能支持他。”。

“The investors who joined in this round recognize our rapid progress, as well as our expansive potential and vision,” says Viswa Colluru, Ph.D., CEO and Founder of Enveda. “In combination with our deep bench of top tier investors, we are in an ideal position to advance our novel medicines into the clinic and to bring hope to waiting patients.”.

Enveda首席执行官兼创始人Viswa Colluru博士表示：“加入本轮投资的投资者认可我们取得的快速进展，以及我们广阔的潜力和愿景。”。“结合我们的顶级投资者，我们处于一个理想的位置，可以将我们的新药推向诊所，并为等待的患者带来希望。”。

The closing of this Series B2 round brings the total capital that Enveda has raised to $230 million.

这轮B2轮的结束使Enveda筹集的总资本达到2.3亿美元。

About Enveda Biosciences

关于Enveda Biosciences

Founded in 2019, Enveda is a biotechnology company aiming to understand and utilize the chemistry that forms the foundation of life. Using their AI-powered tools to identify and characterize the wide range of molecules that are produced by living organisms – the vast majority of which have never been explored by science – Enveda is creating a new database of chemical biodiversity: the library of life.

Enveda成立于2019年，是一家生物技术公司，旨在了解和利用构成生命基础的化学物质。Enveda利用人工智能工具识别和表征生物体产生的各种分子，其中绝大多数从未被科学探索过，正在创建一个新的化学生物多样性数据库：生命库。

By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s pressing clinical needs. For more information on Enveda, visit enveda.com..

通过成长、组织、翻译和搜索这个独特的图书馆，Enveda从生命进化的解决方案中学习，以满足当今迫切的临床需求。有关Enveda的更多信息，请访问Enveda.com。。